Abcellera Biologics Inc
NASDAQ:ABCL
Abcellera Biologics Inc
Research & Development
Abcellera Biologics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Research & Development
-$167.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Research & Development
-CA$531.2k
|
CAGR 3-Years
-112%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-8%
|
|
Abcellera Biologics Inc
Glance View
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
See Also
What is Abcellera Biologics Inc's Research & Development?
Research & Development
-167.3m
USD
Based on the financial report for Dec 31, 2024, Abcellera Biologics Inc's Research & Development amounts to -167.3m USD.
What is Abcellera Biologics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-75%
Over the last year, the Research & Development growth was 5%. The average annual Research & Development growth rates for Abcellera Biologics Inc have been -39% over the past three years , -75% over the past five years .
